A clinical trial involving 42 PD patients (2:1 randomized to NAC or control) demonstrated that a 3-month NAC regimen (50 mg/kg intravenous weekly plus 600 mg oral twice daily, skipping oral doses on infusion days) significantly increased dopamine transporter binding compared with the control group. Here, SLC6A3 is linked to Parkinson disease.